Vildagliptin
It promotes pancreatic insulin secretion by inhibiting the DPP-4 enzyme that degrades the intestinal hormone GLP-1 that is activated upon eating (EMA 2016, Scheen 2011).
Very low risk of hypoglycemia.
Recommended dose: one to two doses daily.
Since the last update we have not found published data on its excretion in breast milk.
Its pharmacokinetic data (EMA 2016, Scheen 2011) - low molecular weight and low percentage of binding to plasma proteins - makes it likely that significant amounts will pass into breast milk.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
Diet, exercise, and breastfeeding improve blood sugar levels.
See below the information of these related products:
- Maternal Diabetes Mellitus (Low Risk probable)
- Saxagliptin (Low Risk probable)
Alternatives
- Sport (Very Low Risk)
- Hypo-Caloric Diet (Very Low Risk)
- Acarbose (Very Low Risk)
- Chlorpropamide (Low Risk probable)
- Tolbutamide (Very Low Risk)
- Miglitol (Very Low Risk)
- Glibenclamide (Very Low Risk)
- Metformin Hydrochloride (Very Low Risk)
Very Low Risk
Compatible. Not risky for breastfeeding or infant.
Low Risk
Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.
High Risk
Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.
Very High Risk
Not recommended. Cessation of breastfeeding or alternative.
Writings
- فيلداغليبتين (Arabic)
- Вильдаглиптин (Cyrillic)
- 维格列汀 (Chinese)
- ビルダグリプチン (Japanese)
- C17H25N3O2 (Molecular formula)
- LAF-237 (Experimental code/s)
Drug trade names
References
- EMA. Vildagliptina. Ficha técnica. 2016 Full text (in our servers)
- EMA. Vildagliptin. Drug Summary 2016 Full text (in our servers)
- Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012Abstract
- Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother. 2012Abstract Full text (link to original source)
- He YL, Serra D, Wang Y, Campestrini J, Riviere GJ, Deacon CF, Holst JJ, Schwartz S, Nielsen JC, Ligueros-Saylan M. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2007Abstract
- He YL, Sadler BM, Sabo R, Balez S, Wang Y, Campestrini J, Laurent A, Ligueros-Saylan M, Howard D. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet. 2007Abstract